Giant cell arteritis patients may be able to reduce treatment, study suggests

NCT ID NCT07108387

Recruiting now Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study looks at whether people with giant cell arteritis (GCA) who are in remission can safely stop or lower their dose of tocilizumab (Actemra). About 78 adults who have been on high-dose tocilizumab for at least a year and off steroids for three months will either stop the drug or take a lower dose. Researchers will track how many have a disease flare over 18 months to find the best long-term management strategy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS (GCA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Giant Cell Arteritis temporal arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GIANT CELL ARTERITIS (GCA)

Contacts and locations

Locations

Emory University School of Medicine: Division of Rheumatology
RECRUITING

Atlanta, Georgia, 30307, United States
Hospital for Special Surgery, New York: Division of Rheumatology
RECRUITING

New York, New York, 10021, United States
Johns Hopkins Hospital: Division of Rheumatology Vasculitis Center
RECRUITING

Baltimore, Maryland, 21287, United States
Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases
RECRUITING

Boston, Massachusetts, 02114, United States
Northwell Health: Division of Rheumatology and Allergy-Clinical Immunology
RECRUITING

Great Neck, New York, 11021, United States
Northwestern University
RECRUITING

Chicago, Illinois, 60611, United States
University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology
RECRUITING

Pittsburgh, Pennsylvania, 15217, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.